Abstract
Objectives
To evaluate the usefulness of normalising intra-tumour tracer accumulation on 18F-fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) to reference tissue uptake for characterisation of peripheral nerve sheath tumours (PNSTs) in neurofibromatosis type 1 (NF1) compared with the established maximum standardised uptake value (SUVmax) cut-off of >3.5.
Methods
Forty-nine patients underwent FDG PET/CT. Intra-tumour tracer uptake (SUVmax) was normalised to three different reference tissues (tumour-to-liver, tumour-to-muscle and tumour-to-fat ratios). Receiver operating characteristic (ROC) analyses were used out to assess the diagnostic performance. Histopathology and follow-up served as the reference standard.
Results
Intra-tumour tracer uptake correlated significantly with liver uptake (r s = 0.58, P = 0.016). On ROC analysis, the optimum threshold for tumour-to-liver ratio was >2.6 (AUC = 0.9735). Both the SUVmax cut-off value of >3.5 and a tumour-to-liver ratio >2.6 provided a sensitivity of 100 %, but specificity was significantly higher for the latter (90.3 % vs 79.8 %; P = 0.013).
Conclusions
In patients with NF1, quantitative 18F-FDG PET imaging may identify malignant change in neurofibromas with high accuracy. Specificity could be significantly increased by using the tumour-to-liver ratio. The authors recommend further evaluation of a tumour-to-liver ratio cut-off value of >2.6 for diagnostic intervention planning.
Key Points
• 18 F-FDG PET/CT is used for detecting malignancy in PNSTs in NF1 patients
• An SUV max cut-off value may give false-positive results for benign plexiform neurofibromas
• Specificity can be significantly increased using a tumour-to-liver ratio
Similar content being viewed by others
References
Listernick R, Charrow J (1990) Neurofibromatosis type 1 in childhood. J Pediatr 116:845–853
Conference Statement (1988) Neurofibromatosis. Conference statement. National Institutes of Health Consensus Development Conference. Arch Neurol 45:575–578
Ramanathan RC, Thomas JM (1999) Malignant peripheral nerve sheath tumours associated with von Recklinghausen’s neurofibromatosis. Eur J Surg Oncol 25:190–193
McGaughran JM, Harris DI, Donnai D et al (1999) A clinical study of type 1 neurofibromatosis in north west England. J Med Genet 36:197–203
Ferner RE, Gutmann DH (2002) International consensus statement on malignant peripheral nerve sheath tumors in neurofibromatosis. Cancer Res 62:1573–1577
Ducatman BS, Scheithauer BW, Piepgras DG et al (1986) Malignant peripheral nerve sheath tumors. A clinicopathologic study of 120 cases. Cancer 57:2006–2021
Evans DGR, Baser ME, McGaughran J et al (2002) Malignant peripheral nerve sheath tumours in neurofibromatosis 1. J Med Genet 39:311–314
Lawrence W, Donegan WL, Natarajan N et al (1987) Adult soft tissue sarcomas. A pattern of care survey of the American College of Surgeons. Ann Surg 205:349–359
Korf BR (1999) Plexiform neurofibromas. Am J Med Genet 89:31–37
Mautner VF, Hartmann M, Kluwe L et al (2006) MRI growth patterns of plexiform neurofibromas in patients with neurofibromatosis type 1. Neuroradiology 48:160–165
Tucker T, Wolkenstein P, Revuz J et al (2005) Association between benign and malignant peripheral nerve sheath tumors in NF1. Neurology 65:205–211
Boellaard R (2009) Standards for PET image acquisition and quantitative data analysis. J Nucl Med 50:11S–20S
Jaskowiak CJ, Bianco JA, Perlman SB, Fine JP (2005) Influence of reconstruction iterations on 18F-FDG PET/CT standardized uptake values. J Nucl Med 46:424–428
Warbey VS, Ferner RE, Dunn JT et al (2009) [18F]FDG PET/CT in the diagnosis of malignant peripheral nerve sheath tumours in neurofibromatosis type-1. Eur J Nucl Med Mol Imaging 36:751–757
Ferner RE, Golding JF, Smith M et al (2008) [18F]2-fluoro-2-deoxy-D-glucose positron emission tomography (FDG PET) as a diagnostic tool for neurofibromatosis 1 (NF1) associated malignant peripheral nerve sheath tumours (MPNSTs): a long-term clinical study. Ann Oncol 19:390–394
Brenner W, Friedrich RE, Gawad KA et al (2006) Prognostic relevance of FDG PET in patients with neurofibromatosis type-1 and malignant peripheral nerve sheath tumours. Eur J Nucl Med Mol Imaging 33:428–432
Benz MR, Czernin J, Dry SM et al (2010) Quantitative F18-fluorodeoxyglucose positron emission tomography accurately characterizes peripheral nerve sheath tumors as malignant or benign. Cancer 116:451–458
Salamon J, Derlin T, Bannas P et al (2012) Evaluation of intratumoural heterogeneity on (18)F-FDG PET/CT for characterization of peripheral nerve sheath tumours in neurofibromatosis type 1. Eur J Nucl Med Mol Imaging 40:685–692
Lindholm P, Minn H, Leskinen-Kallio S et al (1993) Influence of the blood glucose concentration on FDG uptake in cancer—a PET study. J Nucl Med 34:1–6
Visvikis D, Cheze-LeRest C, Costa DC et al (2001) Influence of OSEM and segmented attenuation correction in the calculation of standardised uptake values for [18F]FDG PET. Eur J Nucl Med 28:1326–1335
Thie JA (2004) Understanding the standardized uptake value, its methods, and implications for usage. J Nucl Med 45:1431–1434
Meignan M, Gallamini A, Haioun C (2009) Report on the first international workshop on interim-PET-scan in lymphoma. Leuk Lymphoma 50:1257–1260
Barrington SF, Qian W, Somer EJ et al (2010) Concordance between four European centres of PET reporting criteria designed for use in multicentre trials in Hodgkin lymphoma. Eur J Nucl Med Mol Imaging 37:1824–1833
Lee JW, Paeng JC, Kang KW et al (2009) Prediction of tumor recurrence by 18F-FDG PET in liver transplantation for hepatocellular carcinoma. J Nucl Med 50:682–687
Trojani M, Contesso G, Coindre JM et al (1984) Soft-tissue sarcomas of adults; study of pathological prognostic variables and definition of a histopathological grading system. Int J Cancer 33:37–42
Lin BT, Weiss LM, Medeiros LJ (1997) Neurofibroma and cellular neurofibroma with atypia: a report of 14 tumors. Am J Surg Pathol 21:1443–1449
Treglia G, Taralli S, Bertagna F et al (2012) Usefulness of whole-body fluorine-18-fluorodeoxyglucose positron emission tomography in patients with neurofibromatosis type 1: a systematic review. Radiol Res Pract 2012:431029
Khan MA, Combs CS, Brunt EM et al (2000) Positron emission tomography scanning in the evaluation of hepatocellular carcinoma. J Hepatol 32:792–797
Furth C, Amthauer H, Hautzel H et al (2011) Evaluation of interim PET response criteria in paediatric Hodgkin’s lymphoma—results for dedicated assessment criteria in a blinded dual-centre read. Ann Oncol 22:1198–1203
Eary JF, Link JM, Muzi M et al (2011) Multiagent PET for risk characterization in sarcoma. J Nucl Med 52:541–546
Buck AK, Herrmann K, Büschenfelde CM zum et al (2008) Imaging bone and soft tissue tumors with the proliferation marker [18F]fluorodeoxythymidine. Clin Cancer Res 14:2970–2977
Wasa J, Nishida Y, Tsukushi S et al (2010) MRI features in the differentiation of malignant peripheral nerve sheath tumors and neurofibromas. AJR Am J Roentgenol 194:1568–1574
Matsumine A, Kusuzaki K, Nakamura T et al (2009) Differentiation between neurofibromas and malignant peripheral nerve sheath tumors in neurofibromatosis 1 evaluated by MRI. J Cancer Res Clin Oncol 135:891–900
Derlin T, Tornquist K, Münster S et al (2013) Comparative effectiveness of 18F-FDG PET/CT versus whole-body MRI for detection of malignant peripheral nerve sheath tumors in neurofibromatosis type 1. Clin Nucl Med 38:e19–e25
Acknowledgements
Victor F. Mautner and Thorsten Derlin contributed equally.
Parts of the cohort of patients in this retrospective study have been used for the evaluation of the relevance of intra-tumoural heterogeneity: Salamon J, Derlin T, Bannas P et al (2013) Evaluation of intra-tumoural heterogeneity on (18)F-FDG PET/CT for characterization of peripheral nerve sheath tumours in neurofibromatosis type 1. Eur J Nucl Med Mol Imaging 40:685-692.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Salamon, J., Veldhoen, S., Apostolova, I. et al. 18F-FDG PET/CT for detection of malignant peripheral nerve sheath tumours in neurofibromatosis type 1: tumour-to-liver ratio is superior to an SUVmax cut-off. Eur Radiol 24, 405–412 (2014). https://doi.org/10.1007/s00330-013-3020-x
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00330-013-3020-x